MARINUS PHARMACEUTICALS INC's ticker is and the CUSIP is 56854Q200. A total of 106 filers reported holding MARINUS PHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is 0.13 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $8,014,218 | -17.9% | 995,555 | +10.7% | 0.00% | -100.0% |
| Q2 2023 | $9,766,159 | +831.3% | 899,278 | +491.7% | 0.00% | – |
| Q1 2023 | $1,048,634 | -7.3% | 151,976 | -46.5% | 0.00% | – |
| Q4 2022 | $1,130,924 | +41.5% | 284,152 | +136.4% | 0.00% | – |
| Q3 2022 | $799,000 | +26.8% | 120,176 | -7.7% | 0.00% | – |
| Q2 2022 | $630,000 | -89.8% | 130,176 | -80.3% | 0.00% | – |
| Q1 2022 | $6,176,000 | -24.5% | 660,519 | -4.0% | 0.00% | – |
| Q4 2021 | $8,177,000 | +0.0% | 688,272 | -4.2% | 0.00% | – |
| Q3 2021 | $8,175,000 | -30.3% | 718,354 | +9.8% | 0.00% | -100.0% |
| Q2 2021 | $11,732,000 | +48.3% | 653,946 | +28.0% | 0.00% | – |
| Q1 2021 | $7,910,000 | +4.1% | 510,950 | -18.0% | 0.00% | – |
| Q4 2020 | $7,599,000 | +54.3% | 622,907 | +62.5% | 0.00% | – |
| Q3 2020 | $4,925,000 | – | 383,295 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Lion Point Capital, LP | 2,145,337 | $17,269,963 | 7.70% |
| Bleichroeder LP | 1,872,463 | $15,073,327 | 3.72% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 5,204,942 | $41,899,783 | 2.26% |
| Opaleye Management Inc. | 584,000 | $4,701,200 | 1.53% |
| Bain Capital Life Sciences Investors, LLC | 1,431,058 | $11,520,017 | 1.29% |
| Cormorant Asset Management, LP | 2,625,000 | $21,131,250 | 1.23% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 290,000 | $2,337,400 | 0.79% |
| Ikarian Capital, LLC | 746,069 | $6,005,856 | 0.72% |
| Eventide Asset Management | 4,529,997 | $36,466,476 | 0.66% |
| Altium Capital Management LP | 125,033 | $1,006,516 | 0.52% |